Phase II Study of PTK787/ZK222584 in Multiple Myeloma
Patients will take PTK orally once a day for the duration of their time on the study. Each
cycle of chemotherapy will last for 4 weeks.
Measurement of vital signs will be done weekly during the first month of treatment.
Physical exam, vital signs, blood work, a quality of life assessment, and x-ray or MRI wil
be performed every 4 weeks.
Patients will remain on the study until their disease fails to respond to treatment or there
are intolerable side effects. Typically treatment is performed for 12 weeks and up to one
year in patients that are stable and responding.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the effectiveness of PTK in treating patients with relapsed or refractory myeloma
Nikhil Munshi, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|